Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexander L Ling

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
Neuro-Oncology|November 23, 2023
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?Ethan Chen, Alexander L Ling, David A Reardon, et al.
Journal of Cancer Science and Clinical Therapeutics|March 4, 2024
Simplicity: Web-Based Visualization and Analysis of High-Throughput Cancer Cell Line ScreensAlexander L Ling, Weijie Zhang, Adam Lee, et al.
Journal of Cancer Science and Clinical Therapeutics|February 12, 2024
A Web Application for Predicting Drug Combination Efficacy Using Monotherapy Data and IDAComboYunong Xia, Alexander L Ling, Weijie Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Simplicity: web-based visualization and analysis of high-throughput cancer cell line screensAlexander L Ling, Weijie Zhang, Adam Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2023
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint InhibitorsJoseph Toker, J Bryan Iorgulescu, Alexander L Ling, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2023
Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modelingWeijie Zhang, Adam M Lee, Sampreeti Jena, et al.
Cell Reports. Medicine|April 15, 2023
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM modelsMykola Zdioruk, Jorge-Luis Jimenez-Macias, Michal Oskar Nowicki, et al.
Cell|February 12, 2026
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trialMaxime Meylan, Ye Tian, Lijian Wu, et al.
Nature Communications|April 24, 2025
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunityUpasana Sahu, Matthew P Mullarkey, Sara A Murphy, et al.
Nature Communications|June 17, 2026
IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in gliomaEleni Panagioti, Hunter J Kelley, Alexander L Ling, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
Neuro-Oncology|November 23, 2023
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?Ethan Chen, Alexander L Ling, David A Reardon, et al.
Journal of Cancer Science and Clinical Therapeutics|March 4, 2024
Simplicity: Web-Based Visualization and Analysis of High-Throughput Cancer Cell Line ScreensAlexander L Ling, Weijie Zhang, Adam Lee, et al.
Journal of Cancer Science and Clinical Therapeutics|February 12, 2024
A Web Application for Predicting Drug Combination Efficacy Using Monotherapy Data and IDAComboYunong Xia, Alexander L Ling, Weijie Zhang, et al.
Biorxiv : the Preprint Server for Biology|September 25, 2023
Simplicity: web-based visualization and analysis of high-throughput cancer cell line screensAlexander L Ling, Weijie Zhang, Adam Lee, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2023
Clinical Importance of the lncRNA NEAT1 in Cancer Patients Treated with Immune Checkpoint InhibitorsJoseph Toker, J Bryan Iorgulescu, Alexander L Ling, et al.
Proceedings of the National Academy of Sciences of the United States of America|April 17, 2023
Computational drug discovery for castration-resistant prostate cancers through in vitro drug response modelingWeijie Zhang, Adam M Lee, Sampreeti Jena, et al.
Cell Reports. Medicine|April 15, 2023
PPRX-1701, a nanoparticle formulation of 6'-bromoindirubin acetoxime, improves delivery and shows efficacy in preclinical GBM modelsMykola Zdioruk, Jorge-Luis Jimenez-Macias, Michal Oskar Nowicki, et al.
Cell|February 12, 2026
Persistent T cell activation and cytotoxicity against glioblastoma following single oncolytic virus treatment in a clinical trialMaxime Meylan, Ye Tian, Lijian Wu, et al.
Nature Communications|April 24, 2025
IDH status dictates oHSV mediated metabolic reprogramming affecting anti-tumor immunityUpasana Sahu, Matthew P Mullarkey, Sara A Murphy, et al.
Nature Communications|June 17, 2026
IDH1-R132H enhances oncolytic HSV-1 therapy by facilitating viral entry and immune activation in gliomaEleni Panagioti, Hunter J Kelley, Alexander L Ling, et al.
Pageof 2